A status update for a clinical trial involving octreotide was recorded on October 16, 2026. The trial, titled "Treatment of Orthostatic Intolerance," is registered under identifier NCT00262470. It is listed as Phase 1/Phase 2. According to the update, the trial's current status is active, not recruiting. This means the study is ongoing but is no longer enrolling new participants. No results or outcome data were included in this update. The event data does not specify findings, efficacy, or safety conclusions related to octreotide in this trial. Octreotide remains an approved compound, and this trial update reflects only its enrollment and operational status, not any new approval or label change. Readers interested in tracking this study further can refer to the official trial registration for additional procedural details. For broader context on octreotide, including its approved uses and background, readers can consult the compound overview.
Octreotide Trial "Treatment of Orthostatic Intolerance" Now Active, Not Recruiting
See the full octreotide overview
Source: https://clinicaltrials.gov/study/NCT00262470